Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 26, Number 9—September 2020
Dispatch

Human Borrelia miyamotoi Infection, Austria

Selma TobudicComments to Author , Heinz Burgmann, Gerold Stanek, Stefan Winkler, Anna-Margarita Schötta, Markus Obermüller, Mateusz Markowicz, and Heimo Lagler
Author affiliations: Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria (S. Tobudic, H. Burgmann, S. Winkler, M. Obermüller, H. Lagler); Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna (G. Stanek, A.-M. Schötta, M. Markowicz)

Suggested citation for this article

Abstract

We report a human case of Borrelia miyamotoi infection diagnosed in Austria. Spirochetes were detected in Giemsa-stained blood smears. The presence of B. miyamotoi in the patient’s blood was confirmed by PCR, and phylogenetic analysis identified an infection with a strain from Europe.

Borrelia miyamotoi is a relapsing fever spirochete transmitted by the same genus of ticks that transmits B. burgdorferi sensu lato (s.l.), Anaplasma phagocytophilum, Babesia species, and tickborne flaviviruses (13). B. miyamotoi has been documented in ticks from the United States and in numerous countries in Europe (including Russia), as well as in Japan (1,46). B. miyamotoi also has been found in Ixodes scapularis ticks in the northeastern and north-central United States and adjoining areas of Canada, in I. pacificus ticks in the far western United States and British Columbia, in I. ricinus ticks in Europe, and in I. persulcatus ticks in Europe and Asia (1,7,8). I. pavlovskyi and I. ovatus ticks in northern Asia are 2 other species that have been shown to carry B. miyamotoi (9). Endemic areas of B. miyamotoi in Ixodes ticks overlap with those of B. burgdorferi s.l. but with 10-fold lower prevalence (4). Co-infection of Ixodes ticks with both spirochetes also has been identified (9).

Unlike Lyme borreliosis, patients with B. miyamotoi disease typically do not have skin lesions but instead have a nonspecific febrile illness, potentially associated with leukopenia, thrombocytopenia, and elevated liver function parameters (10). Highly immunocompromised patients might have chronic meningitis (2). Untreated patients with B. miyamotoi disease might experience a limited number of recurrent episodes of fever, similar to other relapsing fevers caused by Borrelia infections (6). The same antibiotic regimens used to treat Lyme borreliosis (e.g., 10−14-day courses of oral doxycycline or amoxicillin) are effective for B. miyamotoi disease. Parenteral therapy with ceftriaxone would be preferred for patients with meningitis (3).

Diagnosis of B. miyamotoi disease should be considered in any patient who has fever attacks and resides in or has spent time during tick season in a region where Lyme borreliosis is endemic. Diagnosis requires confirmation using PCR. If the density of spirochetes in the blood is >104/mL, spirochetes might be identified by examining several high-power fields of the blood smear or centifuged sample of cerebrospinal fluid stained with Giemsa or Wright stain (10). Several PCR assays can detect B. miyamotoi in whole blood, plasma, and cerebrospinal fluid by using primers specific for 16S ribosomal RNA and for the flaB and glpQ genes (2,3,8). Serologic testing based on glycerophosphodiester phosphodiesterase antigen of B. miyamotoi that is not found in B. burgdorferi s.l. is highly sensitive but only on convalescent-phase serum specimens (11).

The Case-Patient

A 51-year-old woman who had a long medical history of seropositive rheumatoid arthritis treated with rituximab sought care at our outpatient clinic for relapsing fever that started 3 months before. Fever episodes occurred every 5 days, and duration ranged from 2 to 3 days. Four weeks before the onset of symptoms, the patient had returned from a 3-week trip through the United States, where, as a tourist, she visited the East and West Coasts and stayed in several national parks. She reported several insect bites and 1 tick bite without erythema migrans that occurred while she was in the United States but did not notice any tick bites before or after her travel. After her return, the patient did not travel abroad again but spent her time in her home in lower Austria.

Figure 1

Thumbnail of Timeline of the course of symptoms and treatment, including laboratory test results, for a patient with Borrelia miyamotoi infection (including Giemsa stain of thin blood smear on day 92), Austria. Arrows indicate spirochetes. Original magnification × 100.

Figure 1. Timeline of the course of symptoms and treatment, including laboratory test results, for a patient with Borrelia miyamotoi infection (including Giemsa stain of thin blood smear on day 92), Austria. Arrows...

Figure 2

Thumbnail of Phylogenetic tree based on the 16S rRNA gene of Borrelia miyamotoi from a patient in Austria (Bm4667; arrow) and reference sequences. This phylogenetic tree was constructed by using the maximum-likelihood method based on the general time reversible model. The tree is drawn to scale, with bootstrap values shown at the nodes of the tree, inferred from 600 replicates. A total of 1,199 bp of B. miyamotoi 16S rRNA gene sequences was used in the final dataset, which involved 34 nt sequenc

Figure 2. Phylogenetic tree based on the 16S rRNA gene of Borrelia miyamotoi from a patient in Austria (Bm4667; arrow) and reference sequences. This phylogenetic tree was constructed by using the maximum-likelihood method...

No abnormal findings were observed on physical examination; in particular, no apparent rash on the skin was noted. Routine laboratory tests performed were normal (including kidney and liver function tests), except for the evidence of leukopenia with 3.3 × 109 cells/L (reference range 4–10 × 109 cells/L) and slightly elevated C-reactive protein of 3.5 mg/dL (reference range <0.5 mg/dL). Multiple blood and urine cultures were negative (Figure 1). An initial peripheral Giemsa-stained blood smear was performed during an afebrile period without any result, but when the test was repeated during the next fever episode, spirochetes were detected between blood cells (Figure 1). Detection of spirochetes in blood smear, which is not typical in cases of B. miyamotoi infection, could be attributable to prolonged spirochetemia likely associated with rituximab therapy. Borrelia spp. was identified in a routinely broad-range bacterial 16S gene-based PCR test (SepsiTest-UMD; Molzym GmbH & Co. KG, https://www.molzym.com). DNA was extracted from EDTA blood, and a real-time PCR assay specific for B. miyamotoi targeting the glpQ gene (5) was positive. To confirm the genospecies present in the patient’s blood, further PCRs targeting the 16S–23S internal transcribed spacer region (12,13), 16S rRNA, and glpQ gene (14,15) were performed, and amplicons were sent to a laboratory for bidirectional sequencing (Microsynth, Vienna, Austria). All PCRs confirmed the presence of B. miyamotoi in the patient’s blood, and all yielded 100% identity to various B. miyamotoi strains in the GenBank database. Using MEGA7 (https://www.megasoftware.net), we constructed a phylogenetic tree for our isolate Bm4667 on the basis of the obtained 16S rRNA gene sequence (Figure 2). All 3 sequences obtained during this investigation were submitted to GenBank (accession no. MN515386 for the 16S rRNA gene, MT396940 for the glpQ gene, and MT396941 for the 16S–23S internal transcribed spacer region).

The patient was treated with 200 mg doxycycline once daily for 2 weeks. On the first day of antibiotic administration, the patient was admitted to our hospital for observation in case of potential Jarisch–Herxheimer reaction. However, during the therapy, no reaction or adverse effects were detected. The patient recovered successfully, and no signs of recurrence were observed in the following 6 months.

Conclusions

We describe a human case of B. miyamotoi infection diagnosed in Austria. Although the patient’s report of a tick bite in the United States suggested that this infection was an imported case, the phylogenetic analysis of the B. miyamotoi strain clearly indicates an infection with a strain from Europe (and possibly Austria). Clinicians should be aware of the possibility of these infections.

Dr. Tobudic is an internal medicine specialist at the Department of Infection Diseases and Tropical Medicine, Medical University of Vienna. Her research interest includes yeast infections, biofilm research, pathomechanism of antimicrobial resistance, and research of tickborne illness.

Top

Acknowledgment

We thank the patient for providing consent to publish information about her case.

Top

References

  1. Fukunaga  M, Takahashi  Y, Tsuruta  Y, Matsushita  O, Ralph  D, McClelland  M, et al. Genetic and phenotypic analysis of Borrelia miyamotoi sp. nov., isolated from the ixodid tick Ixodes persulcatus, the vector for Lyme disease in Japan. Int J Syst Bacteriol. 1995;45:80410. DOIPubMed
  2. Gugliotta  JL, Goethert  HK, Berardi  VP, Telford  SR III. Meningoencephalitis from Borrelia miyamotoi in an immunocompromised patient. N Engl J Med. 2013;368:2405. DOIPubMed
  3. Hovius  JW, de Wever  B, Sohne  M, Brouwer  MC, Coumou  J, Wagemakers  A, et al. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet. 2013;382:658. DOIPubMed
  4. Crowder  CD, Carolan  HE, Rounds  MA, Honig  V, Mothes  B, Haag  H, et al. Prevalence of Borrelia miyamotoi in Ixodes ticks in Europe and the United States. Emerg Infect Dis. 2014;20:167882. DOIPubMed
  5. Reiter  M, Schötta  AM, Müller  A, Stockinger  H, Stanek  G. A newly established real-time PCR for detection of Borrelia miyamotoi in Ixodes ricinus ticks. Ticks Tick Borne Dis. 2015;6:3038. DOIPubMed
  6. Platonov  AE, Karan  LS, Kolyasnikova  NM, Makhneva  NA, Toporkova  MG, Maleev  VV, et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011;17:181623. DOIPubMed
  7. Scoles  GA, Papero  M, Beati  L, Fish  D. A relapsing fever group spirochete transmitted by Ixodes scapularis ticks. Vector Borne Zoonotic Dis. 2001;1:2134. DOIPubMed
  8. Richter  D, Schlee  DB, Matuschka  FR. Relapsing fever-like spirochetes infecting European vector tick of Lyme disease agent. Emerg Infect Dis. 2003;9:697701. DOIPubMed
  9. Takano  A, Toyomane  K, Konnai  S, Ohashi  K, Nakao  M, Ito  T, et al. Tick surveillance for relapsing fever spirochete Borrelia miyamotoi in Hokkaido, Japan. PLoS One. 2014;9:e104532. DOIPubMed
  10. Krause  PJ, Fish  D, Narasimhan  S, Barbour  AG. Borrelia miyamotoi infection in nature and in humans. Clin Microbiol Infect. 2015;21:6319. DOIPubMed
  11. Schwan  TG, Schrumpf  ME, Hinnebusch  BJ, Anderson  DE Jr, Konkel  ME. GlpQ: an antigen for serological discrimination between relapsing fever and Lyme borreliosis. J Clin Microbiol. 1996;34:248392. DOIPubMed
  12. Bunikis  J, Garpmo  U, Tsao  J, Berglund  J, Fish  D, Barbour  AG. Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe. Microbiology. 2004;150:174155. DOIPubMed
  13. Wilhelmsson  P, Fryland  L, Börjesson  S, Nordgren  J, Bergström  S, Ernerudh  J, et al. Prevalence and diversity of Borrelia species in ticks that have bitten humans in Sweden. J Clin Microbiol. 2010;48:416976. DOIPubMed
  14. Fomenko  NV, Livanova  NN, Borgoiakov  VI, Kozlova  IV, Shulaĭkina  IV, Pukhovskaia  NM, et al. [Detection of Borrelia miyamotoi in ticks Ixodes persulcatus from Russia] [in Russian]. Parazitologiia. 2010;44:20111.PubMed
  15. Fukunaga  M, Hamase  A, Okada  K, Inoue  H, Tsuruta  Y, Miyamoto  K, et al. Characterization of spirochetes isolated from ticks (Ixodes tanuki, Ixodes turdus, and Ixodes columnae) and comparison of the sequences with those of Borrelia burgdorferi sensu lato strains. Appl Environ Microbiol. 1996;62:233844. DOIPubMed

Top

Figures

Top

Suggested citation for this article: Tobudic S, Burgmann H, Stanek G, Winkler S, Schötta A-M, Obermüller M, et al. Human Borrelia miyamotoi infection, Austria. Emerg Infect Dis. 2020 Sep [date cited]. https://doi.org/10.3201/eid2609.191501

DOI: 10.3201/eid2609.191501

Original Publication Date: July 29, 2020

Table of Contents – Volume 26, Number 9—September 2020

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Selma Tobudic, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Währinger Gürtel 18-20, A-1090 Vienna, Austria

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: July 14, 2020
Page updated: July 29, 2020
Page reviewed: July 29, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external